Radiotracer for Dopamine Transporters
PI: Mark M. Goodman
Collaborators
Chemistry - Ronald J Voll, PhD and Jon McConathy, MD,PhD Pharmacology - Clinton, D Kilts, PhD and Tim Ely
Graphical Analysis - John R Votaw, PhD and Margaret Davis, MD
Human Studies - Margaret Davis, MD and Douglas Bremner, MD
Alterations in DAT Density has been implicated in Neurodegenerative Diseases and Psychiatric Disorders
- Parkinson’s Disease
- ADHD
- Alzheimer’s Disease
- Tourette’s Syndrome
CNS DAT is a major pharmacologic target for a varietyof psychoactive drugs.
- Cocaine
- Methylphenidate
In Vivo Dose Dependent Displacement of DAT Ligand, [18F]FECNT, by (-)-Cocaine in the Rhesus Monkey Striatum
Typical [18F]FECNT Images . Dose dependent displacement of activity from the putamen is seen following the cocaine injections at the indicated amounts and time of injection.
Brain tissue TACs in a normal 170 lb male subject injected with 5.84mCi [18F]FECNT.
The brain regions: caudate (t), putamen (n), thalamus (p), brainstem (X), occipital cortex (+) and cerebellum (l)
- Normal (left) H&Y stage 1.5 (center) and stage 4 (right)
Dopamine Neuron Viability in Striatum as traced by FECNT, Dopamine Reuptake Inhibitor, demonstrating that dopamine neurons decline in Parkinson’s Disease.
Comparison of [18F]FECNT tissue-to-cerebellum ratios at 90-min. post-injection of normal subjects and H&Y stage 1.5 and 4 PD patients.
